Probiotics in Irritable Bowel Syndrome: An Immunomodulatory Strategy?

REFERENCES

• Hussein Z, Quigley EM: Complementary and alternative medicine in irritable bowel syndrome. Aliment Pharmacol Ther23 :465– 471,2006 .
   PubMed Web of Science ®Google Scholar
• Atkinson W, Sheldon TA, Shaath N, Whorwell PJ: Food elimination based on IgG antibodies in IBS: A randomised controlled trial. Gut53 :1459– 1464,2004 .
   PubMed Web of Science ®Google Scholar
• Zar S, Mincher L, Benson MJ, Kumar D: Food specific IgG4 antibodies guided exclusion diet improves symptoms and rectal compliance in IBS. Scand J Gastroenterol40 :800– 807,2005 .
   PubMed Web of Science ®Google Scholar
• Quigley EM: The use of probiotics in functional bowel disease. Gastroenterol Clin North Am34 :533– 545,2005 .
   PubMed Web of Science ®Google Scholar
• Schrezenmeir J, de Vrese M: Probiotics, prebiotics, and synbiotics-approaching a definition. Am J Clin Nutr73(Suppl2) :361S– 364S,2001 .
   Google Scholar
• Gibson GR, Roberfroid MB: Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr125 :1401– 1412,1995 .
   PubMed Web of Science ®Google Scholar
• Roberfroid MB: Prebiotics: preferential substrates for specific germs?. Am J Clin Nutr73 (Suppl) :406S– 409S,2001 .
   Google Scholar
• Bouhnik Y, Flourie B, D'Agay-Abensour L, Pochart P, Gramet G, Durand M, Rambaud JC: Administration of transgalacto-oligosaccharides increases fecal bifidobacteria and modifies colonic fermentation metabolism in healthy humans. J Nutr127 :444– 448,1997 .
   PubMed Web of Science ®Google Scholar
• Duggan C, Gannon J, Walker WA: Protective nutrients and functional foods for the gastrointestinal tract. Am J Clin Nutr75 :789– 808,2002 .
   PubMed Web of Science ®Google Scholar
• Gnoth MJ, Kunz C, Kinne-Saffran E, Rudloff S: Human milk oligosaccharidases are minimally digested in vitro. J Nutr130 :3014– 3020,2000 .
   PubMed Web of Science ®Google Scholar
• Dai D, Walker WA: Prospective nutrients and bacterial colonization in the immature human gut. Adv Pediatr46 :353– 382,1999 .
   PubMedGoogle Scholar
• McCarthy J, O'Mahony L, O'Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, Fitzgibbon J, O'Sullivan GC, Kiely B, Collins JK, Shanahan F: Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut52 :975– 980,2003 .
   PubMed Web of Science ®Google Scholar
• Madsen K, Cornish A, Soper P, McKaigney, C, Jijon H, Yachimel C, Doyle J, Jewell L, De Simone C: Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology121 :580– 591,2001 .
   PubMed Web of Science ®Google Scholar
• Hart AL, Lammers K, Brigidi P, Vitali B, Rizzello F, Gionchetti P, Campieri M, Kamm MA, Knight SC, Stagg AJ: Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut53 :1602– 1609,2004 .
   PubMed Web of Science ®Google Scholar
• O'Mahony L, McCarthy J, Kelly P, Shanahan F, Quigley EM: Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology128 :541– 551,2005 .
   PubMed Web of Science ®Google Scholar
• O'Mahony L, O'Callaghan L, McCarthy J, Shilling D, Scully P, Sibartie S, Kavanagh E, Kirwan WO, Redmond RP, Collins JK, Shanahan F: Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans. Am J Physiol290 :G839– G845,2006 .
   PubMed Web of Science ®Google Scholar
• Jijon H, Backer J, Diaz H, Yeung H, Thiel D, McKagney C, De Simone C, Madsen K: DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology126 :1358– 1373,2004 .
   PubMed Web of Science ®Google Scholar
• Drisko J, Bischoff B, Giles C, Adelson M, Rao RV, McCallum R: Evaluation of five probiotic products for label claims by DNA extraction and polymerase chain reaction analysis. Dig Dis Sci50 :1113– 1117,2005 .
   PubMed Web of Science ®Google Scholar
• Madden JA, Hunter JO: A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics. Br J Nutr88(Suppl 1) :S67– S72,2002 .
   Web of Science ®Google Scholar
• Si JM, Yu YC, Fan YJ, Chen SJ.: Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol10 :1802– 1805,2004 .
   PubMed Web of Science ®Google Scholar
• Malinen E, Rinttila T, Kajander K, Matto J, Kassinen A, Krobius L, Saarela M, Korpela R, Palva A: Analysis of the fecal microbiota of irritable bowel patients and healthy controls with real-time PCR. Am J Gastroenterol100 :373– 382,2005 .
   PubMed Web of Science ®Google Scholar
• Sun X, Cai G Wang WG: Observation on intestinal flora in patients of IBS after treatment of Chinese integrative medicine. Zhong Xi Yi Jie He Xue Bao2 :340– 342,2004 .
   PubMedGoogle Scholar
• Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G: The fecal microbial population in the irritable bowel syndrome. Microbiologica5 :185– 194,1982 .
   PubMed Web of Science ®Google Scholar
• Bradley HK, Wyatt GM, Bayliss CE, Hunter JO: Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome. J Med Microbiol23 :29– 32,1987 .
   PubMed Web of Science ®Google Scholar
• King TS, Elia M, Hunter JO: Abnormal colonic fermentation in the irritable bowel syndrome. Lancet352 :1187– 1189,1998 .
   PubMed Web of Science ®Google Scholar
• Pimentel M, Chow EJ, Lin HC: Eradication of small bowel bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol95 :3503– 3506,2000 .
   PubMed Web of Science ®Google Scholar
• Pimentel M, Chow E, Lin H: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol98 :412– 419,2003 .
   PubMed Web of Science ®Google Scholar
• Pimentel M, Wallace D, Hallegua D, Chow E, Kong Y, Park S, Lin HC: A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Ann Rheum Dis63 :450– 452,2004 .
   PubMed Web of Science ®Google Scholar
• Pimentel M, Lin HC, Enayati P, van den Berg B, Lee HR, Chen JH, Park S, Kong Y, Conklin J: Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol29 :G1089– G1095,2006 .
   Google Scholar
• Lin HC: Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA292 :852– 858,2004 .
   PubMed Web of Science ®Google Scholar
• Pimentel M, Soffer EE, Chow EJ, Kong Y, Lin HC: Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test suggesting bacterial overgrowth. Dig Dis Sci47 :2639– 2642,2002 .
   PubMed Web of Science ®Google Scholar
• Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I: A randomized double-blind placebo-controlled trial of rifaxamin in patients with abdominal bloating and flatulence. Am J Gastroenterol101 :326– 333,2006 .
   PubMed Web of Science ®Google Scholar
• Pimentel M, Park S, Mirocha J, Kane SV, Kong Y: The effect of a nonabsorbed antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med145 :557– 563,2006 .
   PubMed Web of Science ®Google Scholar
• Quigley EM, Quera R: Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics and probiotics. Gastroenterology130(2Suppl 1) :S78– S90,2006 .
   Google Scholar
• Jiang T, Savaiano DA: Modification of colonic fermentation by bifidobacteria and ph in vitro: impact on lactose metabolism, short-chain fatty acid, and lactate production. Dig Dis Sci42 :2370– 2377,1997 .
   PubMed Web of Science ®Google Scholar
• Johanson ML, Molin G, Ahrne S, Jeppsson B: Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol95 :1231– 1238,2000 .
   PubMed Web of Science ®Google Scholar
• Kim HJ, Camilleri M, McKenzie S, Lempke MB, Burton DD: A randomized controlled trail of a probiotic, VSL#3 on gut transit and symptoms in diarrhoea-predominant IBS. Aliment Pharmacol Ther17 :895– 904,2003 .
   PubMed Web of Science ®Google Scholar
• Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G, Zinsmeister AR: A randomised controlled trial of probiotic combination VSL#3 and placebo in IBS with bloating: Neurogastroenterol Motil17 :687– 696,2005 .
   PubMed Web of Science ®Google Scholar
• Kajander K, Hatakka K, Poussa T, Farkkila M, Korpela R: A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther22 :387– 394,2005 .
   PubMed Web of Science ®Google Scholar
• Niv E, Naftali T, Hallak R, Vaisman N: The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome - a double blind, placebo-controlled, randomized study. Clin Nutr24 :925– 931,2005 .
   PubMed Web of Science ®Google Scholar
• Tsuchiya J, Barreto R, Okura R, Kawakita S, Fesce E, Marotta F: Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis5 :169– 174,2004 .
   PubMedGoogle Scholar
• Sen S, Mulan MM, Parker TJ, Tarry SA, Hunter JO: Effect of Lactobacillus plantarum 299V on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci47 :2615– 2620,2002 .
   PubMed Web of Science ®Google Scholar
• Bausserman M, Michail S: The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr147 :197– 201,2005 .
   PubMed Web of Science ®Google Scholar
• Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D: Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol152 :735– 741,2001 .
   PubMed Web of Science ®Google Scholar
• Quigley EM: Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management. Chin J Dig Dis8 :2– 7,2007 .
   Google Scholar
• Cotter PD, Hill C, Ross RP: Bacteriocins: developing innate immunity for food. Nat Rev Microbiol3 :777– 788,2005 .
   PubMed Web of Science ®Google Scholar
• Castigliuolo I, Riegler MF, Valenick L, La Mont JT, Pothoulakis C: Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun67 :302– 307,1999 .
   PubMed Web of Science ®Google Scholar
• Spiller RC: Estimating the importance of infection in IBS. Am J Gastroenterol98 :238– 241,2003 .
   PubMed Web of Science ®Google Scholar
• Spiller RC: Postinfectious irritable bowel syndrome. Gastroenterology124 :1662– 1571,2003 .
   PubMed Web of Science ®Google Scholar
• Mearin F, Perez-Oliveras M, Perello A, Vinyet J, Ibanez A, Coderch J, Perona M: Dyspepsia and irritable bowel syndrome after a Salmonella outbreak: a one year follow-up cohort study. Gastroenterology129 :98– 104,2005 .
   PubMed Web of Science ®Google Scholar
• Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF: Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev CD003048,2004 .
   Google Scholar
• Gwee K-A, Leong Y-L, Graham C, McKendrick MW, Collins SM, Walters SJ, Underwood JE, Read NW: The role of psychological and biological factors in post-infective gut dysfunction. Gut44 :400– 406,1999 .
   PubMed Web of Science ®Google Scholar
• Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR: Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut47 :804– 811,2000 .
   PubMed Web of Science ®Google Scholar
• Dunlop SP, Jenkins D, Neal KR, Spiller RC: Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology125 :1651– 1659,2003 .
   PubMed Web of Science ®Google Scholar
• Gwee KA, Collins SM, Read NW, Rajnakova A, Deng Y, Graham JC, McKendrick MW, Moochhala SM: Increased rectal mucosal expression of interleukin 1 beta in recently acquired post-infectious irritable bowel syndrome. Gut52 :523– 526,2003 .
   PubMed Web of Science ®Google Scholar
• Chadwick V, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I: Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology122 :1778– 1783,2002 .
   PubMed Web of Science ®Google Scholar
• Dinan TG, Quigley EM, Ahmed SM, Scully P, O'Brien S, O'Mahony L, O'Mahony S, Shanahan F, Keeling PW: Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology130 :304– 311,2006 .
   PubMed Web of Science ®Google Scholar
• Khalif IL, Quigley EM, Konovitch EA, Maximova ID: Alterations in the colonic flora and intestinal permeability and evidence of immune activation in chronic constipation. Dig Liver Dis37 :838– 849,2005 .
   PubMedGoogle Scholar
• Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, Akira S, Takeda K, Lee J, Takabayashi K, Raz E: Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology126 :520– 528,2004 .
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M: Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology124 :1202– 1209,2003 .
   PubMed Web of Science ®Google Scholar
• Mimuar T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA: Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut53 :108– 114,2004 .
   PubMed Web of Science ®Google Scholar
• Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV: Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut52 :91– 93,2003 .
   PubMed Web of Science ®Google Scholar
• van der Veek PP, van der Berg M, de Kroon YE, Verspaget HW, Masclee AA: Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol100 :2510– 2516,2005 .
   PubMed Web of Science ®Google Scholar
• Quigley EM: Disturbances of motility and visceral hypersensitivity in irritable bowel syndrome: biological markers or epiphenomenon. Gastroenterol Clin North Am.34 :221– 233,2005 .
   PubMed Web of Science ®Google Scholar
• Lawal A, Kern M, Sidhu H, Hofmann C, Shaker R: Novel evidence for hypersensitivity of visceral sensory neural circuitry in irritable bowel syndrome patients. Gastroenterology130 :26– 33,2006 .
   PubMed Web of Science ®Google Scholar
• Camilleri M: Testing the sensitivity hypothesis in practice: tools and methods, assumptions and pitfalls. Gut51 :i34– i40,2002 .
   Google Scholar
• Bouin M, Plourde V, Boivin M, Riberdy M, Lupien F, Laganiere P, Verrier P, Poitras P: Rectal distension testing in patients with the irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology122 :1771– 1777,2002 .
   PubMed Web of Science ®Google Scholar
• McKee DP, Quigley EMM: Intestinal motility in irritable bowel syndrome: Is IBS a motility disorder? Part 1: Definition of IBS and colonic motility. Dig Dis Sci38 :1761– 1772,1993 .
   PubMed Web of Science ®Google Scholar
• McKee DP, Quigley EMM: Intestinal motility in irritable bowel syndrome: Is IBS a motility disorder? Part 2: Motility of the small bowel, esophagus, stomach and gall bladder. Dig Dis Sci38 :1763– 1782,1993 .
   Google Scholar
• Quigley EMM: Disturbances in small bowel motility. Bailliere's Best Pract Res Clin Gastroenterol13 :385– 395,1999 .
   PubMed Web of Science ®Google Scholar
• Collins SM: A case for an immunological basis for irritable bowel syndrome. Gastroenterology122 :2078– 2080,2002 .
   PubMed Web of Science ®Google Scholar
• Mayer EA, Collins SM: Evolving pathophysiological models of functional gastrointestinal disorders. Gastroenterology122 :2032– 2048,2002 .
   PubMed Web of Science ®Google Scholar
• Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R: Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology126 :693– 702,2004 .
   PubMed Web of Science ®Google Scholar
• Verdu EF, Bercik P, Bergonzelli GE, Huang XX, Blenerhasset P, Rochat F, Fiaux M, Mansourian R, Corthesy-Theulaz I, Collins SM: Lactobacillus paracasei normalizes muscle hypercontractiltiy in a murine model of postinfective gut dysfunction. Gastroenterology127 :826– 837,2004 .
   PubMed Web of Science ®Google Scholar
• Verdu EF, Bercik P, Verma-Gandhu M, Huang X-X, Blenerhasset P, Jackson W, Mao Y, Wang L, Rochat F, Collins SM: Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut55 :182– 190,2006 .
   PubMed Web of Science ®Google Scholar
• Ait-Belgnaoui A, Han W, Lamine F, Eutamene H, Fioramonti J, Bueno L, Theodorou V: Lactobacillus farciminis treatment suppresses stress-induced visceral hypersensitivity: a possible action through interaction with epithelial cells cytoskeleton contraction. Gut55 :1090– 1094,2006 .
   PubMed Web of Science ®Google Scholar
• Kamiya T, Wang L, Forsythe P, Goettsche G, Mao Y, Wang Y, Tougas G, Bienenstock J: Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut55 :191– 196,2006 .
   PubMed Web of Science ®Google Scholar
• Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L Dubuquoy C, Merour E, Geboes K, Chamaillard M, Ouwehand A, Leyer G, Carcano D, Colombel JF, Ardid D, Desreumaux P: Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med.13 :35– 37,2007 .
   PubMed Web of Science ®Google Scholar
• Resta-Lenert S, Barrett KE: Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut52 :988– 997,2003 .
   PubMed Web of Science ®Google Scholar
• Zareie M, Johnson-Henry KC, Jury J, Yang PC, Ngan BY, McKay DM, Soderholm JD, Perdue MH, Sherman PM: Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut55 :1553– 1560,2006 .
   PubMed Web of Science ®Google Scholar
• Hobday D, Thompson DG: Role of functional brain imaging in gastroenterology in health and disease. Digest Liver Dis32 :101– 103,2000 .
   Web of Science ®Google Scholar
• Aziz Q, Thompson DG: Clinical relevance of the gut brain axis. Gastroenterology114 :559– 578,1997 .
   Web of Science ®Google Scholar
• Mertz H, Morgan V, Tanner G, Pickens D, Price R, Shyr Y, Kessler R: Regional cerebral activation in irritable bowel syndrome with painful and nonpainful stimuli. Gastroenterology118 :842– 848,2000 .
   PubMed Web of Science ®Google Scholar
• Patacchioli FR, Angelucci L, Delleba G, Monnazzi P, Leci O: Actual stress, psychopathology and salivary cortisol levels in the irritable bowel syndrome (IBS). J Endocrinol Invest24 :173– 177,2001 .
   PubMed Web of Science ®Google Scholar
• Ellenbruch S, Orr WC: Diarrhea- and constipation-predominant IBS patients differ in postprandial autonomic and cortisol responses. Am J Gastroenterol96 :460– 466,2001 .
   PubMed Web of Science ®Google Scholar
• Beishuizen A, Thijs LG: Endotoxin and the hypothalamic-pituitary-adrenal (HPA) axis. J Endotoxin Res9 :3– 24,2003 .
   PubMedGoogle Scholar
• O'Brien SM, Scully P, Scott LV, Dinan TG: Cytokine profiles in bipolar affective disorders: focus on acutely ill patients. Affect Disord90 :263– 267,2006 .
   PubMed Web of Science ®Google Scholar
• Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, Desimone C, Song XY, Diehl AM: Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology37 :343– 350.
   PubMed Web of Science ®Google Scholar
• Sheil B, McCarthy J, O'Mahony L, Bennett MW, Ryan P, Fitzgibbon JJ, Kiely B, Collins JK, Shanahan F: Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut53 :694– 700,2004 .
   PubMed Web of Science ®Google Scholar
• Whitehead WE, Palsson O, Jones KR: Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology122 :1140– 1156,2002 .
   PubMed Web of Science ®Google Scholar
• Niedzielin K, Kordecki H, Birkenfeld B: A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol13 :1143– 1147,2001 .
   PubMed Web of Science ®Google Scholar
• Halpern GM, Prindiville T, Blankenburg M, Hsia T, Gershwin ME: Treatment of irritable bowel syndrome with lacteol fort: a randomized, double-blind, cross-over trial. Am J Gastroenterol91 :1579– 1585,1996 .
   PubMed Web of Science ®Google Scholar
• O'Sullivan MA, O'Morain CA: Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis32 :302– 304,2000 .
   PubMedGoogle Scholar
• Nobaek S, Johanson ML, Molin G, Ahrne S, Jeppsson B: Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol95 :1231– 1238,2000 .
   PubMed Web of Science ®Google Scholar
• Hamilton-Miller JMT: Probiotics in the Management of Irritable Bowel Syndrome: A Review of Clinical Trials. Microb Ecol Health Dis13 :212– 216,2001 .
   Google Scholar
• Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EMM: Efficacy of an encapsulated probiotic Bifidobacterium Infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol, in press,2006 .
   Google Scholar
• Evans BW, Clark WK, Moore DJ, Whorwell PJ: Tegaserod for the treatment of irritable bowel syndrome. The Cochrane Database of Systematic Reviews2004 , Issue 1. Art. No.: CD003960. DOI: 10.1002/14651858.CD003960.pub2.
   Google Scholar
• Cremonini F, Delgado-Aros S, Camilleri M: Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil15 :79– 86,2003 .
   PubMed Web of Science ®Google Scholar
• Fanigliulo L, Comparato G, Aragona G, Cavallaro L, Iori V, Maino M, Cavestro GM, Soliani P, Sianesi M, Franze A, Di Mario F: Role of gut microflora and probiotic effects in the irritable bowel syndrome. Acta Biomed.77 :85– 89,2006 .
   PubMedGoogle Scholar
• Drisko J, Bischoff B, Hall M, McCallum R.: Treating irritable bowel syndrome with a food elimination diet followed by food challenge and probiotics. J Am Coll Nutr.25 :514– 522,2006 .
   PubMed Web of Science ®Google Scholar